NCT07048496Recruiting
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 6 May 2025
- Start date
- Jul 2025
- Primary completion date
- Feb 2027
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Bladder cancer
- NCT number
- NCT07048496
What you commit to
- Study type: Interventional
- Planned participants: 50
- From Jul 2025 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- inability to receive BCG therapy (i.e. - previous reaction with BCG)
Other illness
- inability to undergo catheterization (i.e. - history of urethral stricture)
Other
- Cohort 1 exclusion criteria
- inability to provide informed consent
- Cohort 2 exclusion criteria
- inability to provide informed consent
- no access to mobile phone
- inability to respond to written conversations in English
Who the study is looking for
- Age 18 years or older;
- completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders
- Age 18 years or older;
- experience with the delivery of BCG delivery for more than 2 years
- Cohort 2 inclusion criteria
- Age 18 years or older;
- diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.